{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:45:41Z","timestamp":1785008741279,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102577","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:46:26Z","timestamp":1748612786000},"page":"102577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Is there a path to cure myasthenia gravis?"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7522-5974","authenticated-orcid":false,"given":"Rozen","family":"Le Panse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102577_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0140-6736(75)92779-8","article-title":"Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis","volume":"2","author":"Aharonov","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102577_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102577_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib5","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2025.102577_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102577_bib7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.145.7.2115","article-title":"Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis","volume":"145","author":"Leprince","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102577_sbref8","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2007206117","article-title":"Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis","volume":"117","author":"Jiang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2025.102577_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF00915041","article-title":"The in vivo effects of corticosteroids on thymocyte subsets in myasthenia gravis","volume":"4","author":"Berrih","year":"1984","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coi.2025.102577_bib10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1212\/01.WNL.0000032502.89361.0C","article-title":"Thymoma in patients with MG: characteristics and long-term outcome","volume":"59","author":"Evoli","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2025.102577_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12016-016-8558-3","article-title":"Thymic germinal centers and corticosteroids in myasthenia gravis: an immunopathological study in 1035 cases and a critical review","volume":"52","author":"Truffault","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coi.2025.102577_sbref12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53595-6","article-title":"Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction","volume":"15","author":"Braun","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102577_bib13","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2025.102577_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2796.2007.01879.x","article-title":"Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis","volume":"263","author":"Wang","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.coi.2025.102577_bib15","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1016\/j.febslet.2011.04.032","article-title":"Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?","volume":"585","author":"Burn","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coi.2025.102577_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.autrev.2008.07.028","article-title":"The role of innate immunity in the induction of autoimmunity","volume":"8","author":"Pisetsky","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102577_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ana.23791","article-title":"Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis","volume":"73","author":"Cufi","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coi.2025.102577_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneuroim.2003.11.013","article-title":"Thymic myoid cells express high levels of muscle genes","volume":"148","author":"Mesnard-Rouiller","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.coi.2025.102577_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","article-title":"Central role of interferon-beta in thymic events leading to myasthenia gravis","volume":"52","author":"Cufi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102577_bib21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102577_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00782","article-title":"Comparative analysis of thymic and blood treg in myasthenia gravis: thymic epithelial cells contribute to thymic immunoregulatory defects","volume":"11","author":"Truffault","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102577_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.imbio.2012.05.006","article-title":"SDF-1\/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients","volume":"218","author":"Weiss","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.coi.2025.102577_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mus.26107","article-title":"Myasthenia gravis with muscle-specific tyrosine kinase antibodies: a narrative review","volume":"58","author":"Morren","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coi.2025.102577_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-014-0283-8","article-title":"Treatment of MuSK-associated myasthenia gravis","volume":"16","author":"El-Salem","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of oral steroid therapy for myasthenia gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0030-1271010","article-title":"Surgical resection of thymoma still represents the first choice of treatment","volume":"60","author":"Ried","year":"2012","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.coi.2025.102577_bib29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102577_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/icvts\/ivt510","article-title":"Is thymectomy in non-thymomatous myasthenia gravis of any benefit?","volume":"18","author":"Diaz","year":"2014","journal-title":"Inter Cardiovasc Thorac Surg"},{"key":"10.1016\/j.coi.2025.102577_bib32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib33","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2025.102577_bib35","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102577_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/jnnp-2022-329834","article-title":"Thymectomy and disease duration in non-thymomatous acetylcholine receptor antibody-positive myasthenia gravis: a single-centre, cross-sectional study","volume":"94","author":"Chung","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coi.2025.102577_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-333189","article-title":"Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: long-term follow-up and safety profile","author":"Chan","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coi.2025.102577_sbref39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/acn3.52246","article-title":"Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation","volume":"12","author":"Beland","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib40","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/acn3.51898","article-title":"Remission of severe myasthenia gravis after autologous stem cell transplantation","volume":"10","author":"Schlatter","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201cRebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib42","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.4049\/jimmunol.165.7.3599","article-title":"Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis","volume":"165","author":"Im","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102577_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0008-8749(03)00118-7","article-title":"Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells","volume":"223","author":"Xiao","year":"2003","journal-title":"Cell Immunol"},{"key":"10.1016\/j.coi.2025.102577_bib44","article-title":"A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens","volume":"48","author":"Almenara-Fuentes","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.coi.2025.102577_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2024-000836","article-title":"Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial","volume":"6","author":"G Brew","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.coi.2025.102577_sbref46","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180012","article-title":"Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity","volume":"134","author":"Bodansky","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coi.2025.102577_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.coi.2025.102577_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102577_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1439899","article-title":"Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: first approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.coi.2025.102577_bib51","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for treatment-refractory antibody-mediated diseases in neurology","volume":"29","author":"Scheibe","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.coi.2025.102577_bib52","article-title":"Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities","volume":"15","author":"Ma","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coi.2025.102577_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102983","article-title":"B cell-specific mAb\u2013siRNA conjugates improve experimental myasthenia","volume":"135","author":"Ibtehaj","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102577_sbref54","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02691-3","article-title":"Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis","volume":"20","author":"Villegas","year":"2023","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.coi.2025.102577_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado2084","article-title":"Engineering CAR-T therapies for autoimmune disease and beyond","volume":"16","author":"English","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102577_sbref56","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2025.102577_sbref57","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coi.2025.102577_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413685","article-title":"Current non-viral-based strategies to manufacture CAR-T cells","volume":"25","author":"Gehrke","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102577_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"key":"10.1016\/j.coi.2025.102577_bib60","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.5966\/sctm.2015-0243","article-title":"Human mesenchymal stem cells impact Th17 and Th1 responses through a prostaglandin E2 and myeloid-dependent mechanism","volume":"5","author":"Rozenberg","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.coi.2025.102577_sbref61","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05450-x","article-title":"Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17\/Treg balance","volume":"22","author":"Hu","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.coi.2025.102577_bib62","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/stem.1881","article-title":"Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells","volume":"33","author":"Franquesa","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.coi.2025.102577_bib63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","article-title":"Human mesenchymal stem cells modulate B-cell functions","volume":"107","author":"Corcione","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102577_bib64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biochi.2024.04.009","article-title":"Mesenchymal stem cells in autoimmune disease: a systematic review and meta-analysis of pre-clinical studies","volume":"223","author":"Swain","year":"2024","journal-title":"Biochimie"},{"key":"10.1016\/j.coi.2025.102577_bib65","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/sctm.16-0485","article-title":"Safety profile of good manufacturing practice manufactured interferon \u03b3-primed mesenchymal stem\/stromal cells for clinical trials","volume":"6","author":"Guess","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.coi.2025.102577_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89665","article-title":"Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model","volume":"2","author":"Sudres","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2025.102577_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-023-03295-7","article-title":"Research progress of engineered mesenchymal stem cells and their derived exosomes and their application in autoimmune\/inflammatory diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.coi.2025.102577_bib68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.tips.2023.04.005","article-title":"Artificial intelligence-driven drug development against autoimmune diseases","volume":"44","author":"Moingeon","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.coi.2025.102577_bib69","article-title":"Artificial intelligence for predicting treatment responses in autoimmune rheumatic diseases: advancements, challenges, and future perspectives","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102577_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103496","article-title":"Machine learning application in autoimmune diseases: state of art and future prospectives","volume":"23","author":"Danieli","year":"2024","journal-title":"Autoimmun Rev"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:04:32Z","timestamp":1779084272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":70,"alternative-id":["S0952791525000536"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102577","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a path to cure myasthenia gravis?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102577"}}